Pentoxifylline

Hemorrheologic agent Xanthine derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 10-30 mg/kg q8-12h Duration: Variable; often 2-4 weeks for dermatologic conditions, longer for chronic diseases
Notes: Start at lower end and titrate up. Administer with food to reduce GI upset.
Cat PO 10-20 mg/kg q12h Duration: Variable; use cautiously due to limited safety data
Notes: May cause GI upset; monitor for vomiting.
Horse PO 8.4 mg/kg q12h Duration: Variable; for laminitis, may use for 2-4 weeks
Notes: Administer on an empty stomach for better absorption.
Cattle PO 10-20 mg/kg q12h Duration: Variable; for mastitis, 3-5 days
Notes: Extra-label use; observe withdrawal times.
Small Ruminants PO 10-20 mg/kg q12h Duration: Variable
Notes: Extra-label use; limited data.
Rabbit PO 10-20 mg/kg q12h Duration: Variable
Notes: Extra-label use; monitor for GI stasis.
Birds/Poultry PO 10-20 mg/kg q12h Duration: Variable
Notes: Extra-label use; limited data.

Clinical Indications & Species Uses

General Indications
  • Improvement of microcirculation in ischemic and inflammatory conditions
  • Adjunctive therapy for immune-mediated diseases
Dog (Canine)
  • Peripheral vascular disease
  • Vasculitis (e.g., steroid-responsive dermatitis arteritis)
  • Dermatomyositis
  • Ischemic dermatopathies
  • Adjunctive therapy for immune-mediated hemolytic anemia (IMHA) to reduce thrombosis risk
  • Chronic otitis externa with vascular compromise
Cat (Feline)
  • Adjunctive therapy for feline infectious peritonitis (FIP) due to anti-TNF effects (experimental)
Horse (Equine)
  • Vasculitis
  • Laminitis (adjunctive therapy to improve microcirculation)
  • Endotoxemia (adjunctive therapy)
  • Equine protozoal myeloencephalitis (EPM) as adjunctive therapy
Cattle (Bovine)
  • Vasculitis
  • Mastitis (adjunctive therapy to reduce inflammation)
  • Respiratory disease complex (adjunctive therapy)

Pharmacology & Mechanism of Action

Drug Class: Hemorrheologic agent | Pharmacological Group: Xanthine derivative

Mechanism of Action: Pentoxifylline is a methylxanthine derivative that improves blood flow by decreasing blood viscosity and increasing erythrocyte flexibility. It inhibits phosphodiesterase, leading to increased intracellular cAMP and ATP in erythrocytes, which enhances their deformability. It also reduces platelet aggregation, decreases fibrinogen levels, and inhibits leukocyte adhesion and activation, thereby improving microcirculation and tissue oxygenation.

Pharmacodynamics: Pentoxifylline exerts hemorrheologic effects by reducing blood viscosity and improving erythrocyte flexibility, which enhances blood flow through small vessels. It also has anti-inflammatory and immunomodulatory properties, including inhibition of tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines. These effects may be beneficial in conditions involving ischemia, inflammation, and microvascular compromise.

⚡ Pharmacokinetics Summary

Absorption: Rapidly and well absorbed after oral administration. Peak plasma concentrations occur within 2-4 hours in most species. Food may delay absorption but not the extent.
Distribution: Widely distributed throughout the body. Crosses the blood-brain barrier and placenta. Volume of distribution is approximately 2-3 L/kg in dogs.
Metabolism: Extensively metabolized in the liver, primarily by oxidation and demethylation. The major active metabolite is 1-(5-hydroxyhexyl)-3,7-dimethylxanthine (metabolite V), which has similar pharmacologic activity.
Excretion: Excreted primarily in the urine as metabolites; less than 4% is excreted unchanged. Biliary excretion also occurs. In dogs, the elimination half-life is approximately 1-2 hours for the parent drug, but the active metabolite may have a longer half-life.
Half-Life: Dogs: 1-2 hours (parent drug); Cats: approximately 1 hour; Horses: approximately 1-2 hours; Cattle: approximately 1-2 hours.
Bioavailability: Oral bioavailability is approximately 20-30% in dogs due to first-pass metabolism, but the active metabolite contributes to overall effect.
Protein Binding: Approximately 20-30% bound to plasma proteins in dogs and humans.

Available Formulations & Strengths

Oral Tablet 400 mg, 500 mg (extended-release) (PO)
Oral Solution 400 mg/5 mL (compounded) (PO)
Injectable Solution 20 mg/mL (for IV use; not commonly used in veterinary medicine) (IV)

Contraindications & Clinical Warnings

Contraindications:
  • Hypersensitivity to pentoxifylline or other xanthines (e.g., caffeine, theophylline)
  • Recent history of bleeding (e.g., cerebral hemorrhage, active bleeding disorders)
  • Concurrent use with strong CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) may increase toxicity
  • Severe hepatic or renal impairment (use with caution)
Warnings & Clinical Precautions:
  • Use with caution in patients with bleeding disorders or those on anticoagulant therapy
  • May cause hypotension; monitor blood pressure in hypotensive patients
  • Use with caution in patients with cardiac disease, especially arrhythmias
  • In food animals, observe withdrawal times; extra-label use requires veterinary oversight
  • Not approved for use in cats; use only when benefits outweigh risks
  • May cause GI upset; administer with food
  • In horses, avoid use in acute laminitis if there is active bleeding or coagulopathy

Adverse Effects & Reactions

Common:

  • Vomiting
  • Diarrhea
  • Nausea
  • Anorexia
  • Agitation
  • Restlessness

Serious / Severe:

  • Bleeding (e.g., gastrointestinal hemorrhage, epistaxis)
  • Hypotension
  • Arrhythmias
  • Seizures (rare)
  • Hepatotoxicity (rare)

Rare:

  • Allergic reactions (rash, urticaria)
  • Thrombocytopenia
  • Leukopenia
  • Cholestatic hepatitis

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Anticoagulants (e.g., warfarin, heparin) Increased risk of bleeding; monitor coagulation parameters High
Antiplatelet drugs (e.g., aspirin, clopidogrel) Additive antiplatelet effects; increased bleeding risk High
Ciprofloxacin and other fluoroquinolones Increased pentoxifylline levels due to CYP1A2 inhibition; risk of toxicity Moderate
Theophylline Additive xanthine effects; increased risk of CNS stimulation and cardiac effects Moderate
Antihypertensives Additive hypotensive effects Moderate
NSAIDs Increased risk of gastrointestinal bleeding Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Vomiting
  • Diarrhea
  • Hypotension
  • Tachycardia
  • Arrhythmias
  • Agitation
  • Tremors
  • Seizures
  • Loss of consciousness

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Induce emesis if recent ingestion and patient is conscious. Administer activated charcoal to reduce absorption. Provide IV fluids for hypotension. Monitor cardiac function and treat arrhythmias as needed. Control seizures with diazepam or barbiturates. There is no specific antidote.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 3 days

Withdrawal times are not established for pentoxifylline in food animals; these are suggested based on pharmacokinetic data. Consult regulatory authorities for specific requirements.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from moisture. Keep in tightly closed container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Approved for use in humans; not FDA-approved for veterinary use, but commonly used extra-label in dogs and horses.

Extra-Label (Off-Label) Use: In the US, extra-label use in food animals is permitted under AMDUCA with veterinary oversight, but requires a valid VCPR and extended withdrawal times. Not approved for use in cats or food animals.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Pentoxifylline is primarily used in veterinary medicine for its hemorrheologic and anti-inflammatory effects. It is most commonly prescribed in dogs for dermatologic conditions such as dermatomyositis and vasculitis, and as an adjunct in immune-mediated hemolytic anemia. In horses, it is used for laminitis and endotoxemia. Clinical response may take several weeks; therefore, a therapeutic trial of at least 2-4 weeks is recommended. Due to its potential to cause GI upset, administering with food is advised. Monitoring for bleeding is important, especially in patients on concurrent anticoagulant therapy. In food animals, extra-label use requires careful consideration of withdrawal times. Overall, pentoxifylline is a valuable adjunctive therapy in various ischemic and inflammatory conditions, but its use should be based on individual patient assessment and evidence-based guidelines.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)